Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the Invesco S&P SmallCap Health Care ETF (PSCH), a passively managed exchange traded fund launched on 04/07/2010.Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.Investor-friendly, sector ETFs provide many options to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Broad is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 3, placing it in top 19%.Index DetailsThe fund is sponsored by Invesco. It has amassed assets over $516.85 M, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Broad segment of the equity market. PSCH seeks to match the performance of the S&P SmallCap 600 Capped Health Care Index before fees and expenses.This Index is comprised of common stocks of U.S. healthcare companies.These are companies that are principally engaged in the business of providing healthcare-related products & services, including biotechnology, pharmaceuticals, medical technology and supplies & facilities and this Index is a subset of the S&P SmallCap 600 Index.CostsSince cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio.Annual operating expenses for this ETF are 0.29%, making it one of the least expensive products in the space.Sector Exposure and Top HoldingsETFs offer a diversified exposure and thus minimize single stock risk but it is still important to delve into a fund's holdings before investing. Most ETFs are very transparent products and many disclose their holdings on a daily basis.This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.Looking at individual holdings, Lhc Group Inc (LHCG) accounts for about 4.30% of total assets, followed by Omnicell Inc (OMCL) and Neogen Corp (NEOG).The top 10 holdings account for about 34.63% of total assets under management.Performance and RiskSo far this year, PSCH has added about 1.19%, and is down about -13.90% in the last one year (as of 05/31/2019). During this past 52-week period, the fund has traded between $100.46 and $144.96.The ETF has a beta of 1.24 and standard deviation of 18.87% for the trailing three-year period, making it a high risk choice in the space. With about 69 holdings, it effectively diversifies company-specific risk.AlternativesInvesco S&P SmallCap Health Care ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PSCH is a reasonable option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.Vanguard Health Care ETF (VHT) tracks MSCI US Investable Market Health Care 25/50 Index and the Health Care Select Sector SPDR Fund (XLV) tracks Health Care Select Sector Index. Vanguard Health Care ETF has $8.84 B in assets, Health Care Select Sector SPDR Fund has $17.68 B. VHT has an expense ratio of 0.10% and XLV charges 0.13%.Bottom LineTo learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Invesco S&P SmallCap Health Care ETF (PSCH): ETF Research Reports Omnicell, Inc. (OMCL): Free Stock Analysis Report Health Care Select Sector SPDR Fund (XLV): ETF Research Reports Vanguard Health Care ETF (VHT): ETF Research Reports Neogen Corporation (NEOG): Free Stock Analysis Report LHC Group (LHCG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research